8.3 Generic Substitution, Biosimilars & Interchangeability
Key Takeaways
- Under the Tennessee Generic Drug Substitution Act (T.C.A. § 53-10-204), a pharmacist must substitute a less expensive, therapeutically equivalent generic drug for a brand-name drug order unless the prescriber directs otherwise or the patient requests the brand-name product.
- To legally prohibit generic substitution in Tennessee, the prescriber must personally write in their own handwriting 'Dispense as Written', 'DAW', or 'Brand Medically Necessary' on the face of the prescription order; preprinted check-boxes or stamps are legally void.
- Under T.C.A. § 53-10-204, the pharmacist must notify the patient of the generic substitution and the associated cost savings; the patient maintains an absolute right to decline generic substitution and receive the brand-name drug.
- Therapeutic equivalence is evaluated under the FDA Orange Book two-letter coding system, where products with an 'A' rating (e.g., AB, AA, AN, AO, AP, AT) are bioequivalent and therapeutically interchangeable with the reference listed drug (RLD), while 'B'-rated products cannot be substituted without prescriber authorization.
- Under T.C.A. § 53-10-209, a pharmacist may substitute an interchangeable biological product for a prescribed reference biologic only if licensed as 'interchangeable' in the FDA Purple Book; within five (5) business days following dispensing, the pharmacist must notify the prescriber of the specific product and manufacturer.
8.3 Generic Substitution, Biosimilars & Interchangeability
Quick Answer: Under the Tennessee Generic Drug Substitution Act (T.C.A. § 53-10-204), pharmacists must substitute a less expensive, therapeutically equivalent generic drug unless the prescriber writes "Dispense as Written" (DAW) or "Brand Medically Necessary" in their own handwriting on the prescription face, or the patient requests the brand. Substitution requires an "A" rating in the FDA Orange Book. Under T.C.A. § 53-10-209, pharmacists may substitute biological products only if designated "interchangeable" in the FDA Purple Book. The pharmacist must notify the patient of generic substitution and must notify the prescriber of an interchangeable biologic substitution within five (5) business days.
1. Tennessee Generic Drug Substitution Act (T.C.A. § 53-10-204)
The Tennessee Generic Drug Substitution Act, codified at T.C.A. §§ 53-10-201 through 53-10-208, establishes a statutory presumption in favor of lower-cost generic pharmaceuticals. The General Assembly enacted this framework to reduce healthcare costs for consumers while ensuring uncompromised therapeutic efficacy.
Mandatory Substitution Mandate
Under T.C.A. § 53-10-204, when a pharmacist receives a prescription written for a brand-name drug, the pharmacist shall dispense a less expensive, therapeutically equivalent generic drug in place of the brand-name drug, provided that:
- The generic substitution is therapeutically equivalent as determined by the FDA;
- The substitution results in a lower cost to the purchaser; and
- The prescriber has not validly instructed that the brand-name drug be dispensed.
Patient Notification and Consent
Under T.C.A. § 53-10-204(b), the pharmacist must notify the patient (or the patient's representative) that a generic substitution has been made and disclose the cost difference between the brand-name and generic drug. The patient retains an absolute statutory right to decline the generic substitution and demand the brand-name product. A pharmacist cannot force generic substitution upon an unwilling patient, even if third-party insurance imposes higher copayments on brand products.
┌─────────────────────────────────────────────────────────────────────────────┐
│ TENNESSEE GENERIC SUBSTITUTION WORKFLOW │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Prescription presented for Brand-Name Drug. │
│ └─> Check prescription face for prescriber prohibition (DAW). │
│ │
│ 2. Did the Prescriber write "DAW" / "Brand Medically Necessary" by hand? │
│ ├─► YES: Dispense Brand Name. Generic substitution is PROHIBITED. │
│ └─► NO: Proceed to step 3. │
│ │
│ 3. Is there an FDA Orange Book "A"-rated therapeutic equivalent? │
│ ├─► NO: Dispense Brand Name. Cannot substitute "B"-rated products. │
│ └─► YES: Proceed to step 4. │
│ │
│ 4. Notify patient of substitution and cost savings. Does patient agree? │
│ ├─► NO (Patient insists on brand): Dispense Brand Name. │
│ └─► YES: Dispense less expensive "A"-rated Generic Equivalent. │
└─────────────────────────────────────────────────────────────────────────────┘
2. Prescriber Prohibition of Substitution ("DAW" Standards)
A critical area of Tennessee jurisprudence is the precise legal mechanism required for a prescriber to prohibit generic substitution:
┌─────────────────────────────────────────────────────────────────────────────┐
│ PRESCRIBER PROHIBITION REQUIREMENTS │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Prescription Format │ Tennessee Statutory Requirement (TCA § 53-10-204)│
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Written Paper Order │ Prescriber MUST handwrite on the face of the │
│ │ prescription: "Dispense as Written", "DAW", │
│ │ "Brand Medically Necessary", or words of │
│ │ similar import in their own handwriting. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Pre-Printed Checkboxes │ **VOID AND UNLAWFUL.** A pre-printed checkbox │
│ on Prescription Blanks │ with "DAW" or two signature lines ('Dispense as │
│ │ Written' vs 'May Substitute') does NOT comply. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Rubber Stamps / Labels │ **VOID.** A rubber stamp or pre-inked "DAW" mark │
│ │ does not satisfy the handwriting requirement. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Oral (Telephone) Order │ Prescriber must explicitly state orally that the │
│ │ brand is medically necessary / DAW. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Electronic Order (EPCS) │ Prescriber must make an affirmative electronic │
│ │ selection (default pre-checks are invalid). │
└──────────────────────────┴──────────────────────────────────────────────────┘
[!IMPORTANT] Under Tennessee law, prescription pads with two signature lines (where one line reads "Dispense as Written" and the other reads "Substitution Permitted") or pre-printed checkboxes with "DAW" are legally insufficient to prevent generic substitution. Unless the prescriber personally writes out "Dispense as Written," "DAW," or "Brand Medically Necessary" in their own handwriting on the prescription face, the pharmacist is legally authorized—and mandated—to substitute a lower-cost generic equivalent.
3. FDA Orange Book: Therapeutic Equivalence Ratings
To substitute a generic drug in Tennessee, the product must be established as therapeutically equivalent in the FDA reference publication: Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book).
The Two-Letter Coding System
Orange Book ratings utilize a two-letter coding system where the first letter designates therapeutic equivalence status:
┌─────────────────────────────────────────────────────────────────────────────┐
│ FDA ORANGE BOOK RATING ARCHITECTURE │
├────────────────────────────────────────┬────────────────────────────────────┤
│ Rating Code │ Regulatory Meaning & Substituted │
├────────────────────────────────────────┼────────────────────────────────────┤
│ **First Letter 'A'** │ **THERAPEUTICALLY EQUIVALENT** to │
│ │ the Reference Listed Drug (RLD). │
│ │ Bioequivalent; substitutable. │
├────────────────────────────────────────┼────────────────────────────────────┤
│ **First Letter 'B'** │ **NOT THERAPEUTICALLY EQUIVALENT** │
│ │ to RLD. Actual/potential bio- │
│ │ equivalence problems. NOT substitutable.│
└────────────────────────────────────────┴────────────────────────────────────┘
Breakdown of "A" Rating Subcategories
- AB: Products meeting necessary bioequivalence requirements through in vivo and/or in vitro testing. Most common rating for solid oral dosage forms (tablets and capsules).
- AA: Oral dosage forms with no known or suspected bioequivalence issues (solutions, conventional tablets).
- AN: Solutions and powders for aerosolization.
- AO: Injectable oil solutions.
- AP: Injectable aqueous solutions.
- AT: Topical products (creams, ointments, gels) meeting bioequivalence standards.
Multi-Source Sub-Codes (AB1, AB2, AB3)
When an innovator drug exists in multiple formulations or reference lines (e.g., diltiazem hydrochloride extended-release capsules or levothyroxine sodium tablets), the FDA assigns numerical suffixes (AB1, AB2, AB3, AB4). Products can only be substituted if they share the exact same alphanumeric rating: an AB1 generic can be substituted for an AB1 reference drug, but an AB1 generic cannot be substituted for an AB2 reference drug without prescriber approval.
Breakdown of "B" Ratings (Non-Substitutable)
Any drug rated with a leading letter "B" (e.g., BC, BD, BE, BN, BP, BR, BS, BT, BX) has either demonstrated bio-inequivalence or lacks adequate bioequivalence documentation. Pharmacists in Tennessee cannot substitute a B-rated product for a prescribed brand-name drug without contacting the prescriber and obtaining an explicit new prescription order.
Narrow Therapeutic Index (NTI) Drugs
Narrow Therapeutic Index drugs are agents where small differences in dose or blood concentration may lead to serious therapeutic failures or life-threatening adverse drug reactions. Examples include: warfarin, levothyroxine, digoxin, carbamazepine, theophylline, lithium, and phenytoin.
- Under FDA and Tennessee standards, NTI drugs may still be substituted if rated AB to the reference product; however, pharmacists should maintain consistent manufacturers across refills and exercise enhanced clinical vigilance.
4. Biologics and Biosimilars Under Tennessee Law (T.C.A. § 53-10-209)
Biological products (biologics) are large, complex molecules derived from living organisms (e.g., monoclonal antibodies, insulins, growth hormones). Because of their complexity, exact generic copies cannot be synthesized. Instead, federal law under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and Tennessee law under T.C.A. § 53-10-209 establish a distinct regulatory regime.
The FDA Purple Book
The FDA publishes the Database of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations (the Purple Book). The Purple Book categorizes biologics into three distinct legal tiers:
┌─────────────────────────────────────────────────────────────────────────────┐
│ BIOLOGICAL REGULATORY HIERARCHY │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Regulatory Tier │ Legal Definition & Substitution Scope │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ 1. Reference Product │ The original innovator biological product │
│ │ licensed under PHSA § 351(a) (e.g., Lantus, │
│ │ Humira, Neupogen). │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ 2. Biosimilar Product │ Highly similar to the reference product with no │
│ │ clinically meaningful differences in safety, │
│ │ purity, and potency. **CANNOT be substituted at │
│ │ the pharmacy counter without prescriber order.** │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ 3. Interchangeable │ Meets additional standards: expected to produce │
│ Biological Product │ the same clinical result in any patient; risk of │
│ │ alternating/switching is not greater than using │
│ │ reference product. **MAY BE SUBSTITUTED at the │
│ │ pharmacy counter without contacting prescriber.**│
└──────────────────────────┴──────────────────────────────────────────────────┘
[!WARNING] Biosimilar vs. Interchangeable: A biological product that is only licensed as "biosimilar" is NOT automatically substitutable at the pharmacy level. A pharmacist who receives a prescription for Lantus cannot dispense a biosimilar like Semglee unless the FDA has granted Semglee the specific regulatory designation of Interchangeable Biological Product in the Purple Book.
5. Prescriber Notification Mandate for Interchangeables (5 Business Days)
When a pharmacist substitutes an interchangeable biological product for a prescribed reference biologic under T.C.A. § 53-10-209, Tennessee law enforces an affirmative prescriber notification rule:
┌─────────────────────────────────────────────────────────────────────────────┐
│ INTERCHANGEABLE BIOLOGIC DISPENSING: STATUTORY MANDATES │
├─────────────────────────────────────────────────────────────────────────────┤
│ Authority: T.C.A. § 53-10-209 │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Verification: Product must be designated "interchangeable" in Purple Book│
│ 2. Cost: Substitution must result in lower cost to purchaser. │
│ 3. Prescriber Instructions: Prescriber has not written "DAW". │
│ 4. Patient Notification: Inform patient of substitution. │
│ 5. Prescriber Notification: WITHIN FIVE (5) BUSINESS DAYS of dispensing, │
│ the pharmacist must communicate the specific product name and manufacturer│
│ to the prescribing practitioner. │
└─────────────────────────────────────────────────────────────────────────────┘
Methods of Prescriber Communication
Under T.C.A. § 53-10-209(b), the communication must specify the exact product name and manufacturer of the interchangeable biologic dispensed. Notice may be communicated through:
- An interoperable electronic medical records (EMR) system;
- An electronic prescribing technology;
- A pharmacy benefit management (PBM) system;
- A pharmacy record that the prescriber can query electronically;
- Facsimile (fax), telephone, or secure email if electronic systems are unavailable.
Statutory Exceptions to Notification
Prescriber notification is NOT required if:
- There is no FDA-approved interchangeable biological product available and the prescribed reference product is dispensed as written; OR
- The dispensing is a refill of a prescription where the exact same interchangeable biological product and manufacturer were communicated to the prescriber on the initial dispensing.
6. Master Comparison: Generic Drugs vs. Interchangeable Biologics
| Statutory Feature | Generic Small-Molecule Drugs | Interchangeable Biological Products |
|---|---|---|
| Governing Tennessee Statute | T.C.A. § 53-10-204 | T.C.A. § 53-10-209 |
| Federal Reference Source | FDA Orange Book | FDA Purple Book |
| Equivalence Standard | Bioequivalence ('A' rating: AB, AA, etc.) | Interchangeability designation |
| Prescriber Prohibition | Handwritten "DAW" or "Brand Medically Necessary" | Handwritten "DAW" or "Brand Medically Necessary" |
| Patient Notification | Mandatory notification of substitution | Mandatory notification of substitution |
| Prescriber Notification | No notification required | Mandatory within 5 business days |
| Label Requirement | Generic name + Manufacturer/Distributor | Brand/Generic name + Manufacturer |
7. Practical Exam Scenarios
Scenario 1: Pre-Printed Checkbox on Prescription Pad
Case: A patient presents a written prescription for Lipitor 20 mg. The prescription pad has a printed box next to the words "Dispense as Written," which the physician has checked with a pen mark. The physician signed the prescription on the signature line but did not handwrite any words. Legal Analysis: Under T.C.A. § 53-10-204, a pre-printed checkbox is legally invalid to prohibit generic substitution. Tennessee law mandates that the prescriber personally write "Dispense as Written," "DAW," or "Brand Medically Necessary" in their own handwriting on the face of the prescription. Because the prescriber only checked a box, the pharmacist is legally required to substitute a less expensive, "A"-rated generic atorvastatin, provided the patient does not decline.
Scenario 2: Substituting a Biosimilar vs. Interchangeable
Case: A physician writes a prescription for Humira 40 mg/0.8 mL. A patient arrives requesting a less expensive alternative. The pharmacy stocks a biosimilar that is licensed in the Purple Book as "biosimilar" but not classified as "interchangeable." The pharmacist dispenses the biosimilar to save the patient $600. Legal Analysis: The pharmacist committed an unlawful dispensing violation. Under T.C.A. § 53-10-209, a pharmacist may substitute a biological product only if it has received the specific designation of Interchangeable Biological Product from the FDA in the Purple Book. Standard biosimilars cannot be substituted at the pharmacy level without a new prescription from the prescriber.
Scenario 3: Failing to Notify Prescriber of Interchangeable Biologic
Case: A pharmacist dispenses an interchangeable biological product (Semglee interchangeable) for a prescription written for Lantus on Monday, September 7. The pharmacist records the substitution in the local pharmacy computer but does not communicate the product name and manufacturer to the prescriber, believing the electronic claim adjudication to insurance satisfies the law. Legal Analysis: Under T.C.A. § 53-10-209(b), the pharmacist has an affirmative duty to communicate the specific product name and manufacturer to the prescriber within five (5) business days following the dispensing. Sending a claim to a third-party PBM does not satisfy the statutory notification requirement unless the prescriber has direct electronic access to that system. The pharmacist must transmit notice via EMR, fax, or telephone.
A physician issues a written paper prescription for Norvasc (amlodipine) 10 mg. The physician checks a pre-printed box labeled 'Dispense as Written (DAW)' on the prescription blank. Under the Tennessee Generic Drug Substitution Act (T.C.A. § 53-10-204), how must the pharmacist process this prescription?
A community pharmacist receives a new prescription for an expensive reference biological product. The pharmacy stocks an FDA Purple Book-listed biological product that is licensed as 'interchangeable'. Under T.C.A. § 53-10-209, what affirmative notification step is legally required of the pharmacist following substitution?
When evaluating therapeutic equivalence for potential generic substitution under Tennessee law, which of the following FDA Orange Book rating codes indicates that the generic formulation has demonstrated bioequivalence and may be lawfully substituted for the reference listed drug?
A retail pharmacist in Knoxville receives a prescription for Lantus (insulin glargine reference biologic). The pharmacy carries a biosimilar product that is licensed in the FDA Purple Book solely as 'biosimilar' (not designated as 'interchangeable'). The patient requests the cheapest available product. How must the pharmacist proceed under T.C.A. § 53-10-209?